Synthesis and pharmacokinetic properties of novel cPLA2α inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure

Bioorganic & Medicinal Chemistry
2023.0

Abstract

Indole-5-carboxylic acids with 3-aryloxy-2‑oxopropyl residues in position 1 have been shown to be potent inhibitors of cytosolic phospholipase A<sub>2</sub>α (cPLA<sub>2</sub>α), an enzyme involved in the formation of pro-inflammatory lipid mediators. Unfortunately, in animal experiments, only very low plasma concentrations could be achieved after peroral administration of this type of compound. Since insufficient metabolic stability was suspected as the cause, structural modifications were made to optimize this property. These included the conversion of the aromatic into an aliphatic carboxylic acid function as well as the rigidification of the lipophilic structural elements. A selected pyrrole-3-propionic acid was tested for its peroral in vivo bioavailability in mice. However, higher plasma concentrations could not be achieved also with this compound. Using the Caco2 cell permeation assay, substances investigated were found to be very good substrates for gastrointestinal efflux transporters, which explains their poor peroral absorption.

Knowledge Graph

Similar Paper

Synthesis and pharmacokinetic properties of novel cPLA2α inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure
Bioorganic &amp; Medicinal Chemistry 2023.0
1-(5-Carboxyindol-1-yl)propan-2-one Inhibitors of Human Cytosolic Phospholipase A<sub>2</sub>α: Effect of Substituents in Position 3 of the Indole Scaffold on Inhibitory Potency, Metabolic Stability, Solubility, and Bioavailability
Journal of Medicinal Chemistry 2010.0
Structure–activity relationship studies on 1-(2-oxopropyl)indole-5-carboxylic acids acting as inhibitors of cytosolic phospholipase A2α: Effect of substituents at the indole 3-position on activity, solubility, and metabolic stability
European Journal of Medicinal Chemistry 2017.0
1-(5-Carboxyindol-1-yl)propan-2-one Inhibitors of Human Cytosolic Phospholipase A<sub>2</sub>α with Reduced Lipophilicity: Synthesis, Biological Activity, Metabolic Stability, Solubility, Bioavailability, And Topical in Vivo Activity
Journal of Medicinal Chemistry 2010.0
Pyrrolidine Inhibitors of Human Cytosolic Phospholipase A<sub>2</sub>
Journal of Medicinal Chemistry 2000.0
Indole Cytosolic Phospholipase A<sub>2</sub>α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic Acid, Efipladib
Journal of Medicinal Chemistry 2008.0
Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: Synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4′-yl(oyl)] piperazines
Bioorganic &amp; Medicinal Chemistry 2008.0
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2
Bioorganic &amp; Medicinal Chemistry Letters 2001.0
Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents
European Journal of Medicinal Chemistry 2016.0
9,11-Epoxy-9-homo-14-oxaprosta-5-enoic acid derivatives. Novel inhibitors of fatty acid cyclooxygenase
Journal of Medicinal Chemistry 1986.0